10-QPeriod: Q2 FY2024

Medtronic plc Quarterly Report for Q2 Ended Oct 27, 2023

Filed November 30, 2023For Securities:MDT

Summary

Medtronic plc reported solid financial results for the second quarter of fiscal year 2024, with net sales increasing by 5% to $7.98 billion and diluted earnings per share (EPS) of $0.68 compared to $0.32 in the prior year quarter. For the six-month period, net sales grew 5% to $15.69 billion, and diluted EPS was $1.28, up from $1.02 in the prior year. The company demonstrated continued revenue growth across its key segments, including Cardiovascular, Neuroscience, Medical Surgical, and Diabetes, driven by strong performance in specific product lines like Micra, TAVR, Core Spine, and the MiniMed 780G insulin pump system. Despite facing inflationary pressures and supply chain challenges, Medtronic maintained its commitment to innovation and strategic growth initiatives, including pending acquisitions and new product launches, positioning the company for sustained performance.

Financial Highlights

55 data points
Beta

Revenue

$7.98B

65.4% Gross Margin

Net Income

$911.00M

11.4% Net Margin

EPS (Diluted)

$0.68

Total Assets

$90.09B

Cash & Equivalents

$1.31B

Free Cash Flow

$200.00M

Financial Statements
Beta
Revenue$7.98B
Cost of Revenue$2.76B
Gross Profit$5.22B
SG&A Expenses$2.69B
Operating Income$1.34B
Interest Expense$180.00M
Net Income$911.00M
EPS (Basic)$0.68
EPS (Diluted)$0.68
Shares Outstanding (Basic)1.33B
Shares Outstanding (Diluted)1.33B

Key Highlights

  • 1Net sales increased by 5% to $7.98 billion for the second quarter of fiscal year 2024, and by 5% to $15.69 billion for the first six months.
  • 2Diluted Earnings Per Share (EPS) was $0.68 for the quarter, a significant increase from $0.32 in the prior year, and $1.28 for the six-month period, up from $1.02.
  • 3All four major business segments (Cardiovascular, Neuroscience, Medical Surgical, and Diabetes) showed year-over-year revenue growth.
  • 4The Cardiovascular segment saw a 6% increase in net sales, driven by products like Micra and TAVR.
  • 5The Neuroscience segment's net sales grew 5%, with strong contributions from Core Spine and Neurosurgery.
  • 6The Diabetes segment reported a 10% increase in net sales for the quarter, driven by the MiniMed 780G insulin pump system's global expansion.
  • 7Medtronic repurchased approximately 2.3 million shares for $186 million during the fiscal second quarter under its $6.0 billion share repurchase program, with approximately $2.0 billion remaining.

Frequently Asked Questions

Medtronic reported a 5% increase in net sales for the second quarter of fiscal year 2024, reaching $7.98 billion, compared to $7.59 billion in the same period last year. This growth was driven by increases across most product lines and businesses.

Profitability saw a significant improvement. Diluted earnings per share (EPS) more than doubled to $0.68 from $0.32 in the prior year's second quarter. For the six-month period, diluted EPS increased to $1.28 from $1.02.

All four major segments showed growth. The Diabetes segment had a notable 10% increase in net sales for the quarter, driven by the international expansion of the MiniMed 780G insulin pump system. Cardiovascular and Medical Surgical segments both grew by 6% and 7% respectively for the quarter, while Neuroscience saw a 5% increase.

Medtronic's future growth is expected to be driven by continued adoption of key products such as the Micra transcatheter pacing system, TAVR devices, the MiniMed 780G insulin pump system, and advancements in their neuroscience portfolio. The company also continues to invest in R&D and pursue strategic acquisitions.

Medtronic repurchased approximately 2.3 million shares for $186 million during the fiscal second quarter, as part of its ongoing $6.0 billion share repurchase program. Approximately $2.0 billion remains authorized for future repurchases, indicating a continued focus on returning value to shareholders.